Development Programme
Introduction.
PresSura is developing a single compound, EU-C-001, across a number of neurological conditions in which a rise in intracranial pressure and other proteins plays a central role.
Moderate to Severe
Traumatic Brain Injury
EU-C-001 is in a Phase 2A double-blind trial in moderate to severe TBI across multiple countries. The trial has completed enrolment and follows a Phase 1 programme and an open-label phase.
Stroke and Other
Neurological Conditions
PresSura is targetting stroke as a leading indication in its development program. A preclinical primary pharmacology programme has been completed and a full Phase 1 safety data package in healthy volunteers is available. Plans for a Phase 2A Proof of Concept study are in development.
Concussion Related
Conditions
PresSura is targeting mild TBI (concussion) building on its current moderate to severe TBI trial. A focussed preclinical primary pharmacology programme in concussion and a Phase 1 in healthy volunteers are complete; a Phase 2A programme in mTBI is being planned.
Portfolio.
PRECLINICAL
PHASE 1
PHASE 2A
PHASE 3
Moderate/severe TBI
Stroke
Concussion / PCS
IP.
A strong IP portfolio covering the various indications, with patent life ranging from 2034 to 2040. IP managed through Davies Collison Cave, a leading international IP firm headquartered in Melbourne.
Portfolio.
IP.
A strong IP portfolio covering the various indications, with patent life ranging from 2034 to 2040. IP managed through Davies Collison Cave, a leading international IP firm headquartered in Melbourne.